Yutaka Kishida

Summary

Affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine,Osaka Kaisei Hospital
Location: Osaka City, Japan
Summary:
Education: 1982 Ph.D. (Dr. of Medical Science), Osaka University, Osaka City, Osaka, Japan (Thesis: Studies on in vivo hepatic tissue oxygenation by means of a micro oxygen electrode.)1974 M.D., Nara Prefectural College of Medicine, Kashihara City, Nara, Japan 1967 Graduated from Kyoto
Professional Training and Employment:
2010.8-present Director, Division of Gastroenterology and Hepatology, Department of Inrenal Medicine, Osaka Kaisei Hospital
2008.5- 2010.7 Medical Staff, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Osaka Kaisei Hospital,Osaka City, Osaka, Japan
2003.1-2008.4 Medical Staff, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Osaka Prefectural General Medical Center, Osaka City, Osaka, Japan
1992.5-2002.12 Medical Staff, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Osaka Kosei-NenkinHospital, Osaka City, Osaka, Japan
1985.4-1992.4 Medical Staff, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Osaka Rousai Hospital, Sakai City, Osaka, Japan
1983.4-1985.3 Medical Staff, Department of Internal Medicine, Shin-SenriHospital, Suita City, Osaka, Japan
1982.7-1983.3 Medical Staff, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Osaka Prefectural Hospital, Osaka City, Osaka, Japan
1976.9-1982.6 Research Fellow, Division of Gastroenterology and Hepatology, 1st Department of Internal Medicine, Osaka University Medical School, Osaka City, Osaka, Japan
1974.6-1976.8 Medical Staff, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Osaka Prefectural Hospital, Osaka City, Osaka, Japan

Societies: Japanese Society of Internal Medicine
Japanese Society of Gastroenterology
Japanese Society of Hepatology
Japanese Society of Gastroenterlogical Endoscopy
Japanese Cancer Association
American Gastroenterological Association
American Association for the Advancement of Science
Asian Pacific Association for the Study of
the Liver

Publications:
BIBLIOGRAPHY

1. Toru Koyama, Yutaka Kishida, Nobuhiro Sato and Takenobu Kamada. The quantitative change of mitochondrial and microsomal enzymes in livers in drinkers. Acta Hepatologica Japonica 1977; 18: 943-949
2. Yutaka Kishida, Nobuhiro Sato and Takenobu Kamada. The study of in vivo hepatic tissue oxygenation using a tissue oxygen microelectrode and reflectance spectrophotometry. Japanese Journal of Medicalelectronics and Engineering. 1980; 18: 968-969
3. Yutaka Kishida, Nobuhiro Sato and Takenobu Kamada. Measurement of in vivo hepatic tissue oxygen tension using a tissue oxygen microelectrode. Acta Hepatologica Japonica. 1981; 22: 303
4. Yutaka Kishida, Nobuhiro Sato and Takenobu Kamada. The study of in vivo hepatic tissue oxygen tension in hypovolemic shock. Acta Hepatologica Japonica. 1981; 22: 450
5. Yutaka Kishida, Nobuhiro Sato and Takenobu Kamada. Effect of oxygen and CO2 on in vivo hepatic tissue oxygen tension measured by a tissue oxygen microelectrode. Acta Hepatologica Japonica. 1982; 23: 857-863
6. Haruya Meren, Yutaka Kishida, Nobuhiro Sato and Takenobu Kamada. Effect of ethanol ingestion on carbon tetrachloride treated rat liver. Significance of hepatic tissue oxygen electrode and reflectance spectrophotometry. Hepatology. 1982; 2: 174
7. Yutaka Kishida, Nobuhiro Sato and Takenobu Kamada. Hepatic oxygenation during degeneration of the liver in rats treated with carbon tetrachloride. Acta Hepatologica Japonica. 1982; 23: 1249-1255
8. Yutaka Kishida. Studies on in vivo hepatic tissue oxygenation by means of a micro oxygen electrode. Osaka University Medical Journal. 1982; 34: 1-8
9. Yutaka Kishida, Nobuhiro Sato and Takenobu Kamada. Studies on in vivo hepatic tissue oxygenation in rats treated with chronic ethanol consumption. Acta Hepatologica Japonica. 1983; 24: 699-703
10. Nobuhiro Sato, Yutaka Kishida, Haruya Meren and Takenobu Kamada. Effect of acute and chronic ethanol consumption on hepatic tissue oxygen tension in rats. Pharmacology Biochemistry and Behavior. 1983; 18: 443-447
11. Yutaka Kishida and Teruhisa Akeyama. Effect of Pronase (KHP-1) on chronic active hepatitis. Medicine and Pharmacology. 1987; 18: 1073-1086
12. Teruji Ooka and Yutaka Kishida. Effect of combination therapy of recombinant interferon and immunopotentiation on non A non B chronic hepatitis. Viral hepatitis and liver disease (Alan R. Liss, Inc.). 1988; 891-894
13. Yutaka Kishida, Teruhisa Akeyama and Yoji Shimizu. Effect of combination therapy of interferon and sho-saikotou on chronic hepatitis B. Oriental Medicine. 1989; 13: 24
14. Yutaka Kishida, Teruhisa Akeyama and Yoji Shimizu. Effect of combination therapy of interferon beta and oriental herb on chronic hepatitis B. Progress in Medicine. 1991; 11: 514-523
15. Yutaka Kishida, Teruhisa Akeyama and Yoji Shimizu. Effect of combination therapy of natural interferon beta and Sho-saikotou on chronic hepatitis B. Biomedica. 1991; 6: 93-97
16. Masahide Oshita, Norio Hayashi, Akinori Kasahara, Nobuyuki Yuki, Tetsuro Takehara, Yutaka Kishida, Hideyuki Fusamoto and Takenobu Kamada. Prevalence of hepatitis C virus in family members of patients with hepatitis C. Journal of Medical Virology. 1993; 41: 251-255
17. Yutaka Kishida, Toru Kashiwagi, Teruhisa Akeyama, Norio Hayashi and Takenobu Kamada. Effect of interferon gamma and interferon beta therapy on serum IgM HBc antibody in chronic hepatitis B. The international Symposium on Viral Hepatitis and Liver Disease (Tokyo, Japan), May 10, 1993
18. Yutaka Kishida, Norio Hayashi and Takenobu Kamada. Effect of interferon gamma and interferon beta for chronic hepatitis B. Journal of Clinical Gastroenterology. 1994; 9: 645-652
19. Yutaka Kishida. Combination therapy of interferon and Oriental medicine. Oriental Medicine and Modern Medicine. 1994; 3: 133-137
20. Yutaka Kishida, Takashi Yuasa, Akihito Itoh, Jun Tamaki, Masatsugu Azuma, Toru Kashiwagi and Yasushi Kobayashi. Effect of interferon on hepatic fibrosis in chronic hepatitis C. Analysis of hepatic extracellular matrix component using semiquantitative scoring system. Bulletin of Kosei-Nenkin Hospitals. 1994; 21: 107-117
21. Yutaka Kishida, Kazuhiro Katayama, Norio Hayashi and Takenobu Kamada. Effect of interferon gamma and beta in treatment of chronic hepatitis B. International Hepatotlogy Communication. 1995; 3: 6-14
22. Akinori Kasahara, Norio Hayashi, Naoki Hiramatsu, Masahide Oshita, Hideki Hagihara, Yutaka Kishida, Kazuhiro Katayama, Manabu Masuzawa and Haruhisa Yoshihara. Ability of prolonged interferon treatment to suppress relaps after cessation of therapy in patients with chronic hepatitis C. A multicenter randomized control trial. Hepatotlogy. 1995; 21: 291-297
23. Yutaka Kishida, Yasushi Kobayashi, Toru Kashiwagi, Norio Hayashi and Takenobu Kamada. A histological semiquantitative study of hepatic fibrosis in patients with chronic hepatitis C treated with interferon. 10th Asian Pasific Congress of Gastroentelogy (Yokohama, Japan), October, 1996
24. Yutaka Kishida, Toru Kashiwagi, Harumasa Yoshihara, Takenobu Kamada, Teruhisa Akeyama, Kazuhiro Katayama, Akinori Kasahara and Norio Hayashi.
Long term outcome of chronic hepatitis B patients treated with interferon gamma and beta. The American Association for the Study of the Liver Diseases, (Chicago, Illinois, USA), November, 1997
25. Norio Hayashi, Akinori Kasahara, Masahide Oshita, Kazuhiro Katayama, Manabu Masuzawa, Masahumi Naitoh, Yutaka Kishida, Toru Kashiwagi, Hideyuki Fusamoto and Takenobu Kamada. Evaluation of 6 months course of interferon beta therapy in patients with chronic hepatitis C: Multicenter study.
Medicine and Pharmacology. 1998; 39: 577-584
26. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi, Harumasa Yoshihara, Takenobu Kamada, Teruhisa Akeyama, Akinori Ksahara and Norio Hayashi. Long term follow up of HBe antigen positive chronic hepatitis B treated with gamma and beta interferon. Digestive Diseases Week 1998 (New Orleans, Louisiana USA), May, 1998
27. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Effect of Cyclic and Periodic Interferon Treatment on refractory chronic hepatitis C. 40th Annual Meeting of the Japanese Association of Gastroenterology (Tokyo, Japan). October, 1998
28. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Cyclic and Periodic Interferon Treatment for chronic hepatitis C in non-responder to standard interferon treatment. American Association for the Study of the Liver Diseases (Chicago, Illinois, USA), November, 1998
29. Kazuhiro Katayama, Norio Hayashi, Terukazu Ito, Manabu Masuzawa, Yutaka Kishida, Harumasa Yoshihara, Teruhisa Akeyama, Yoji Shimizu, Akinori Kasahara, Hideyuki Fusamoto and Takenobu Kamada. Clinical efficacy and immunological effects of weekly administration of interferon beta in patients with type B chronic hepatitis. Hepatology. 1999; 14: 212-222
30. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Effect of Cyclic and Periodic Interferon Treatment on cytokines in refractory chronic hepatitis C. 35th Japanese Association for the Study of the Liver Diseases (Tokyo, Japan), June, 1999
31. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Effect of Cyclic and Periodic Interferon Treatment with natural interferon beta and natural interferon alpha on refractory chronic hepatitis C. Digestive Diseases Week Japan 1999 (Hiroshima, Japan), October, 1999
32. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Cyclic and Periodic Interferon Treatment with nIFN beta plus HLBI is effective for non-responders with chronic hepatitis C. 50th American association for the Study of the Liver Diseases (Dallas, Texas, USA), November, 1999
33. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Effect of Cyclic and Periodic Interferon Treatment on immunological cytokine in a patient with refractory chronic hepatitis C. 36th Japanese Association for the Study of the Liver Diseases (Fukuoka, Japan), June, 2000
34. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Effect of Cyclic and Periodic Interferon Treatment on immunological cytokine in a patient with refractory chronic hepatitis C. International association for the Study of the Liver Diseases and Asian Pacific Association for the Study of the Liver Diseases Joint Meeting 2000 (Fukuoka, Japan), June, 2000
35. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Cyclic and Periodic Interferon Treatment repeated with interferon beta induction plus interferon alpha maintenance as a novel approach for interferon non-responder chronic hepatitis C patients with breakthrough. 52nd American association for the Study of the Liver Diseases (Boston, MA, USA), November, 2001
36. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. HCV clearance with Cyclic and Periodic Interferon Treatment consisting of induction treatment with natural interferon beta followed by interferon alpha in interferon-resistant chronic hepatitis C. 38th Japanese Association for the Study of the Liver Diseases (Osaka, Japan), June, 2002
37. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Effect of Cyclic and Periodic Interferon Treatment consisting of induction therapy with natural interferon beta and maintenance therapy with interferon alpha 2b on hepatitis C virus resistant to antiviral therapy. 53rd American Association for the Study of the Liver Diseases (Boston, MA, USA), June, 2002
38. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Effect of optimal Cyclic and Periodic Interferon Treatment regimen consisting of induction treatment with natural interferon beta followed by maintenance treatment with interferon alpha 2b on immuno-regulatory and anti-inflammatory cytokine in interferon-resistant chronic hepatitis C. 39th Japanese Association for the Study of the Liver Diseases (Fukuoka, Japan), May 2003
39. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Clearance of hepatitis C virus with the optimal Cyclic and Periodic Interferon Treatment regimen consisting of induction treatment with natural interferon beta followed by maintenance treatment with interferon alpha in interferon-resistant patients. Digestive Diseases Week 2003 (Orland, Florida, USA), May, 2003
40. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Effect of optimal Cyclic and Periodic Interferon Treatment with natural interferon beta and alpha together with subsequent ribavirin plus interferon alpha treatment on impaired innate and adaptive immunity in patients with resistant hepatitis C. 1st Dominique Dormont international Conference (Paris, France), December, 2004
41. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Effect of Cyclic and Periodic Interferon beta/alpha Treatment with subsequent ribavirin/interferon alpha treatment on innate immunity in chronic hepatitis C with type 1b and high viral load. 41th Japanese Association for the Study of the Liver Diseases (Osaka, Japan), June 2005
42. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Effect of Cyclic and Periodic Interferon beta/alpha Treatment with subsequent ribavirin/interferon alpha 2b treatment on cytokines and chemokines in chronic hepatitis C with type 1b and high viral load. 42th Japanese Association for the Study of the Liver Diseases (Kyoto, Japan), June 2006
43. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Prevention of escape in chronic hepatitis C virus infection with ribavirin plus IFN-alpha 2b or pegylated IFN-alpha 2b: Use of an “induction” approach combining cyclic and periodic interferon treatment with natural IFN-beta and IFN-alpha. 3rd Dominique Dormont International Conference (Bordeaux, France), December, 2006
44. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Prevention of viral escape in chronic hepatitis C with RBV/IFN alpha using an induction with nIFN beta and alpha. The 17th Conference of the Asian Pacific Association of the Study of the Liver Diseases (APASL 2007 in Kyoto, Japan), March, 2007
45. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Ribavirin plus pegylated IFN-alpha 2b using an “induction” approach combining cyclic and periodic interferon treatment with natural IFN-beta and IFN-alpha in refractory chronic hepatitis C. 43th Japanese Association for the Study of the Liver Diseases (Tokyo, Japan), May 2007
46. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. Efficacy of ribavirin and interferon (IFN)-alpha or pegylated IFN-alpha using an “induction approach” involving cyclic and periodic IFN treatment with natural IFN-beta and IFN-alpha for difficult-to-treat chronic hepatitis C with genotype 1b and high viral load. The 18th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2008 in Seoul, Korea), March, 2008
47. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama, Toru Kashiwagi and Norio Hayashi. RBV plus pegylated interferon alpha 2b using an induction approach with Cyclic and periodic interferon treatment in refractory chronic hepatitis C. Digestive Diseases Week Japan 2008 (Tokyo, Japan), October, 2008
48. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama and Toru Kashiwagi. Multiple cytokines profiling of therapeutic responses to ribavirin and pegylated interferon alpha 2b using an “induction” therapy with natural interferon beta in difficult-to-treat chronic hepatitis C. The 13th International Symposium on Viral Hepatitis and Liver Disease (Washington, USA), March, 2009
49. Yutaka Kishida, Masahumi Naitoh, Kazuhiro Katayama and Toru Kashiwagi. Multiple cytokines profiling of therapeutic responses to ribavirin and pegylated interferon alpha 2b using an “induction” therapy with natural interferon beta in difficult-to-treat chronic hepatitis C. Journal of Interferon & Cytokine Research. 2009; (29) 6: 353-368
50. Yutaka Kishida, Yoshimichi Haruna, Masahumi Naitoh, Kazuhiro Katayama and Toru Kashiwagi. Effect of Ribavirin and Pegylated Interferon-alpha2b using an induction approach with natural Interferon-beta on innate immunity in difficult-to-treat chronic hepatitis C. The 7th International Conference on innate immunity (Rhodes, Greece), July, 2010
51. Yutaka Kishida, Effect of Ribavirin and Pegylated Interferon-alpha 2b using an Induction approach with natural nterferon-beta on innate immunity in difficult to-treat chronic hepatitis C. BITs 8th Annual Congress of international Drug and Discovery Science and Technology. Theme: Supporting Syetems for Major Innovative Drugs (Beijing,China), October, 2010
52. Yutaka Kishida. Multiple cytokines profiling of therapeutic responses to ribavirin and pegylated interferon alpha 2b using an “induction” therapy with natural interferon beta in difficult-to-treat chronic hepatitis C. 9th Annual Cytokines and Inflammation. (SanDiego, California, USA), January, 2011
53. Yutaka Kishida. Improvement in anti-hepatitis C virus resistance with Ribavirin and Pegylated-Interferon-alpha using an "Induction" Approach with natural interferon-beta in difficult-to-treat chronic interferon-beta in difficult-to-treat chronic hepatitis C. International Conference and Exhibition on Vaccine & Vaccination. (Philaderphia, USA). November, 2011
54. Yutaka Kishida. Restoration of Innate and Adaptive Immune responses by HCV Viral Inhibition with an Induction Approach using Natural Interferon-Beta in Chronic Hepatitis C. J Clinical and Developmenta Immunology, Special Issue on immune related Disorders and Extrahepatic Diseases in Chronic HCV infection. Vol. 2012,Article ID 582716, 15 pages, doi:10.1155/2012/582716, 2012
55. Yutaka Kishida. Restoration of Innate and Adaptive Immune responses by HCV Viral Inhibition with an Induction Approach using Natural Interferon-Beta in Chronic Hepatitis C. Cold Spring Harbor Asia Conference, Frontiers of Immunology in Health and Diseases. (Zujo China). September, 2012
56. Yutaka Kishida. Restoration of Innate and Adaptive Immune responses by HCV Viral Inhibition with an Induction Approach using Natural Interferon-Beta in Chronic Hepatitis C. 15th Biennial Meeting of European Society for Immunodeficiency. (Florence, Italy),October, 2012


























Publications

  1. Kishida Y, Imaizumi N, Tanimura H, Haruna Y, Kashiwamura S, Kashiwagi T. Restoration of innate and adaptive immune responses by HCV viral inhibition with an induction approach using natural interferon-beta in chronic hepatitis C. Clin Dev Immunol. 2012;2012:582716 pubmed publisher
    ..NCT (n = 8) achieved a higher SVR rate than SOC (n = 8) in difficult-to-treat CHC patients with genotype 1 and high viral loads. ..

Detail Information

Publications1

  1. Kishida Y, Imaizumi N, Tanimura H, Haruna Y, Kashiwamura S, Kashiwagi T. Restoration of innate and adaptive immune responses by HCV viral inhibition with an induction approach using natural interferon-beta in chronic hepatitis C. Clin Dev Immunol. 2012;2012:582716 pubmed publisher
    ..NCT (n = 8) achieved a higher SVR rate than SOC (n = 8) in difficult-to-treat CHC patients with genotype 1 and high viral loads. ..